This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
Brian P. Murray, MD
Advertisement
Articles by Brian P. Murray, MD
Advertisement
Latest Updated Articles
- Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions
Published: February 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
3
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
4
Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer
5
